GlassScriptPhysician profile
Heather Allen Shields
NPI 1487079224
$4,285.39
in general payments reported to CMS, 2019-2025
22 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $874 · 2022: $606 · 2023: $615 · 2024: $1,022 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,015.11 | 2021-2025 | Biktarvy |
| Viiv Healthcare Company | $865.13 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $399.32 | 2021-2025 | Dificid, Zerbaxa, Delstrigo |
| Insmed, INC. | $292.36 | 2021-2025 | Arikayce |
| Melinta Therapeutics, LLC | $260.88 | 2021-2025 | Rezzayo, Orbactiv, Vabomere |
| La Jolla Pharmaceutical Company | $229.64 | 2021-2024 | Xerava |
| Abbvie INC. | $201.87 | 2023-2025 | |
| Csl Behring | $147.94 | 2021-2023 | Hizentra |
| Aimmune Therapeutics, INC. | $137.96 | 2024-2025 | Vowst, Zenpep |
| Paratek Pharmaceuticals, INC. | $135.17 | 2022-2025 | Nuzyra |
| Theratechnologies INC. | $133.30 | 2021-2025 | Egrifta, Trogarzo |
| Shionogi INC | $105.69 | 2021-2025 | Fetroja |
| Janssen Biotech, INC. | $70.66 | 2021-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $57.77 | 2021-2024 | Hyqvia |
| Grifols USA, LLC | $57.63 | 2022-2025 | Xembify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.10 | 2022-2025 | |
| Cormedix INC. | $34.34 | 2025 | Defencath |
| X4 Pharmaceuticals, INC. | $26.98 | 2024 | Xolremdi |
| Sanofi Pasteur INC. | $23.31 | 2025 | |
| Dynavax Technologies Corporation | $16.83 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $16.23 | 2025 | |
| Nabriva Therapeutics, Plc | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.